HSBC Holdings’s Kiniksa Pharmaceuticals KNSA Stock Holding History

HSBC Holdings’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,157	Closed	-$248K	–	3084
2026 Q1	$248K	Buy	+5,157	New	+$228K	﹤0.01%	2527
2025 Q4	–	Sell	-8,080	Closed	-$308K	–	3056
2025 Q3	$308K	Buy	+8,080	New	+$263K	﹤0.01%	2322
2025 Q2	–	Sell	-12,676	Closed	-$280K	–	3130
2025 Q1	$280K	Sell	12,676 -436	-3%	-$8.97K	﹤0.01%	2417
2024 Q4	$257K	Sell	13,112 -554	-4%	-$12.6K	﹤0.01%	2588
2024 Q3	$345K	Buy	+13,666	New	+$333K	﹤0.01%	2242
2024 Q2	–	Sell	-16,356	Closed	-$323K	–	3067
2024 Q1	$323K	Buy	+16,356	New	+$319K	﹤0.01%	2402
2021 Q4	–	Sell	-10,040	Closed	-$115K	–	3307
2021 Q3	$115K	Buy	+10,040	New	+$131K	﹤0.01%	2873
2019 Q4	–	Sell	-14,730	Closed	-$125K	–	3122
2019 Q3	$125K	Buy	+14,730	New	+$163K	﹤0.01%	2955

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

HSBC Holdings's KNSA Position: Q2 2026 in Review

HSBC Holdings sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 5,157 shares — an estimated $248K sold.

HSBC Holdings first reported a position in KNSA in Q3 2019 and held it in 8 quarters. The position peaked at $345K in Q3 2024. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

HSBC Holdings reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
HSBC Holdings sold 5,157 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $248K.
HSBC Holdings first reported a position in Kiniksa Pharmaceuticals in Q3 2019 and held it in 8 quarters.
HSBC Holdings's Kiniksa Pharmaceuticals position peaked at $345K in Q3 2024.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.